Tuberculosis of cervix
ICD-10 A18.16 is a billable code used to indicate a diagnosis of tuberculosis of cervix.
Tuberculosis of the cervix is a rare form of extrapulmonary tuberculosis that primarily affects women, often as a result of hematogenous spread from a primary pulmonary infection. The cervix may become infected through direct extension from adjacent structures or through the lymphatic system. Clinically, patients may present with symptoms such as abnormal vaginal bleeding, pelvic pain, or a palpable mass. Diagnosis is typically confirmed through a combination of clinical evaluation, imaging studies, and laboratory tests, including cervical biopsy, sputum tests, and chest X-rays to rule out pulmonary involvement. Treatment usually involves a prolonged course of antitubercular medications, including isoniazid, rifampicin, ethambutol, and pyrazinamide, with careful monitoring for drug resistance. Public health implications are significant, as tuberculosis is a contagious disease, necessitating contact tracing and isolation procedures for active cases. The management of tuberculosis of the cervix requires a multidisciplinary approach, involving gynecologists, infectious disease specialists, and public health officials to ensure comprehensive care and prevent transmission.
Detailed clinical notes on symptoms, diagnostic tests, and treatment plans.
Patients presenting with abnormal bleeding or pelvic masses.
Need for thorough evaluation to rule out malignancy and other infections.
Comprehensive records of treatment regimens, drug resistance testing, and follow-up care.
Management of tuberculosis in patients with co-morbid conditions.
Monitoring for drug interactions and side effects of antitubercular therapy.
Used when a biopsy is performed to confirm tuberculosis of the cervix.
Document the indication for the biopsy and findings.
Gynecologists should ensure proper technique and follow-up care.
Common symptoms include abnormal vaginal bleeding, pelvic pain, and discharge. Some patients may also experience systemic symptoms such as fever and weight loss.
Diagnosis typically involves a combination of clinical evaluation, imaging studies, cervical biopsy, and laboratory tests, including sputum tests to assess for pulmonary involvement.
Treatment usually consists of a multi-drug regimen including isoniazid, rifampicin, ethambutol, and pyrazinamide, administered over a period of 6 to 12 months, depending on the patient's response and drug resistance.
Public health measures include contact tracing, isolation of active cases, and education on tuberculosis transmission and prevention.
